As clinicians, we often encounter patients with elevated liver enzymes, a clinical puzzle that requires careful interpretation and management. The challenge lies in the broad differential diagnosis, which includes both benign and serious conditions. This article aims to provide a comprehensive approach to managing such cases.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the most commonly evaluated liver enzymes. They are sensitive indicators of hepatocellular injury, but not specific for a particular etiology. Thus, the interpretation of elevated liver enzymes should be done in clinical context, considering patient's history, physical examination and other laboratory findings.
Common causes of elevated liver enzymes include alcohol consumption, viral hepatitis, and non-alcoholic fatty liver disease. Other possibilities include drug-induced liver injury, autoimmune hepatitis, metabolic disorders, and less commonly, malignancies. It is essential to perform a thorough evaluation to identify the underlying cause and to guide management.
Once the etiology has been identified, the management should be tailored accordingly. In cases of alcohol-related liver disease or non-alcoholic fatty liver disease, lifestyle modifications are the cornerstone of treatment. Antiviral therapy is indicated for viral hepatitis. For drug-induced liver injury, discontinuation of the offending drug is usually sufficient. In all cases, patient education and regular follow-up are crucial.
Elevated liver enzymes represent a common yet complex clinical issue. A systematic approach to interpretation and differential diagnosis, followed by an etiology-based management, is the key to optimal patient care. As we continue to advance in our understanding and technology, the enigma of elevated liver enzymes will hopefully become less intimidating, leading to improved patient outcomes.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation